文献速递血栓与止血MDS 与骨髓增殖性肿瘤

骨髓增殖性肿瘤相关脑静脉血栓:三中心74例回顾性研究

Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases.
PubMed 文献 · Am J Hematol · 2021-09-10

该三中心回顾性研究分析了1991至2021年间74例骨髓增殖性肿瘤(MPN)相关脑静脉血栓(CVT)病例,中位年龄44岁,61%为女性。CVT在MPN诊断前、时、后均可发生,91%受检患者携带JAK2V617F,72%以头痛起病。与COVID疫苗相关CVT相比,MPN相关CVT合并其他静脉血栓和脑出血的可能性更低,因而未观察到致命结局。

要点

  • MPN患者CVT可发生于诊断前、时或后,头痛是最常见表现。
  • 91%受检CVT患者携带JAK2V617F,提示其密切关联。
  • MPN相关CVT合并其他静脉血栓和脑出血的可能性低于COVID疫苗相关CVT。

核心结论

  • MPN相关CVT与JAK2V617F、较年轻年龄和女性性别密切相关。
  • 与COVID疫苗相关CVT相比,MPN相关CVT合并其他静脉血栓和脑出血的可能性更低,因而未观察到致命结局。

研究设计与样本

  • 回顾性分析1991至2021年间Mayo Clinic、罗马天主教大学和佛罗伦萨大学三中心74例MPN相关CVT连续病例。
  • 中位年龄44岁(范围15-85),61%为女性。

主要发现

  • CVT在MPN诊断前发生20例(27%),诊断时32例(44%),诊断后22例。
  • 72%患者以头痛起病,横窦(51%)、矢状窦(43%)和乙状窦(35%)受累,10例(14%)出现中枢神经系统出血。
  • 91%受检患者携带JAK2V617F,19例(31%)存在潜在易栓症,10例(14%)有血栓史。
  • 中位随访5.1年(范围0.1-28.6),复发性CVT 3例(4%),复发性动脉血栓11%、复发性静脉血栓9%、大出血14%。
  • 随访神经系统评估显示头痛9例、视力丧失1例、认知障碍1例。

关键数值与推荐

  • MPN疾病别CVT频率:原发性血小板增多症1.3%(39/2893)、真性红细胞增多症1.2%(21/1811)、原发性骨髓纤维化0.2%(3/1888)。

临床怎么用

  • 对MPN患者应警惕CVT风险,尤其JAK2V617F阳性、较年轻和女性患者。
  • MPN相关CVT治疗包括单纯全身抗凝、联合阿司匹林、降细胞治疗或两者联合。

局限性

  • 回顾性设计可能引入选择偏倚和信息偏倚。
  • 部分检测数据不完整(如JAK2V617F仅91%受检患者阳性)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The recent association of cerebral venous thrombosis (CVT) with COVID-19 vaccinations prompted the current retrospective review of 74 cases of CVT (median age = 44 years, range 15-85; 61% females) associated with myeloproliferative neoplasms (MPNs), seen at the Mayo Clinic, Catholic University of Rome, and University of Florence, between 1991 and 2021. Disease-specific frequencies were 1.3% (39/2893), 1.2% (21/1811) and 0.2% (3/1888) for essential thrombocythemia, polycythemia vera and primary myelofibrosis, respectively. Cerebral venous thrombosis occurred either prior to (n = 20, 27%), at (n = 32, 44%) or after (n = 22) MPN diagnosis. A total of 72% of patients presented with headaches. Transverse (51%), sagittal (43%) and sigmoid sinuses (35%) were involved with central nervous system hemorrhage noted in 10 (14%) patients. In all, 91% of tested patients harbored JAK2V617F. An underlying thrombophilic condition was identified in 19 (31%) cases and history of thrombosis in 10 (14%). Treatment for CVT included systemic anticoagulation alone (n = 27) or in conjunction with aspirin (n = 24), cytoreductive therapy (n = 14), or both (n = 9). At a median follow-up of 5.1 years (range 0.1-28.6), recurrent CVT was documented in three (4%) patients while recurrent arterial and venous thromboses and major hemorrhage were recorded in 11%, 9% and 14%, respectively. Follow-up neurological assessment revealed headaches (n = 9), vision loss (n = 1) and cognitive impairment (n = 1). The current study lends clarity to MPN-associated CVT and highlights its close association with JAK2V617F, younger age and female gender. Clinical features that distinguish COVID vaccine-related CVT from MPN-associated CVT include, in the latter, lower likelihood of concurrent venous thromboses and intracerebral hemorrhage; as a result, MPN-associated CVT was not fatal.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Gangat N, Guglielmelli P, Betti S, et al. Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases. Am J Hematol. 2021. PMID: 34453762. doi:10.1002/ajh.26336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。